ProKidney (NASDAQ:PROK) Lowered to “Strong Sell” Rating by Wall Street Zen

Posted by Francis Steltz on May 17th, 2026

Wall Street Zen lowered shares of ProKidney (NASDAQ:PROK – Free Report) from a sell rating to a strong sell rating in a research note released on Saturday morning.

Other analysts have also issued reports about the stock. Jefferies Financial Group upgraded shares of ProKidney to a “strong-buy” rating in a research note on Wednesday, March 18th. Weiss Ratings restated a “sell (d-)” rating on shares of ProKidney in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.40.

Read Our Latest Analysis on PROK

ProKidney Price Performance

Shares of NASDAQ:PROK opened at $1.66 on Friday. The firm has a market capitalization of $501.19 million, a PE ratio of -3.13 and a beta of 1.70. The firm’s 50-day moving average is $1.96 and its two-hundred day moving average is $2.19. ProKidney has a 1 year low of $0.54 and a 1 year high of $7.13.

ProKidney (NASDAQ:PROK – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.10 million. Analysts expect that ProKidney will post -0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On ProKidney

Several hedge funds have recently added to or reduced their stakes in the stock. SummitTX Capital L.P. purchased a new position in ProKidney in the first quarter valued at approximately $26,000. Renaissance Technologies LLC increased its stake in ProKidney by 39.6% in the first quarter. Renaissance Technologies LLC now owns 1,250,794 shares of the company’s stock valued at $2,239,000 after purchasing an additional 355,089 shares during the last quarter. R Squared Ltd purchased a new position in ProKidney in the first quarter valued at approximately $25,000. Virtus Investment Advisers LLC purchased a new position in ProKidney in the fourth quarter valued at approximately $270,000. Finally, Artia Global Partners LP purchased a new position in ProKidney in the fourth quarter valued at approximately $4,118,000. 51.59% of the stock is currently owned by hedge funds and other institutional investors.

About ProKidney

(Get Free Report)

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.